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background:  Previous study showed that 5-azacytidine (5AZ), an inhibitor of DNA methylation, ameliorated cardiac injury by modulating 
macrophage phenotypes. In this study, we investigated the underlying mechanism of 5AZ on macrophage in the anti-inflammatory effects.
methods:  A mouse macrophage cell line RAW264.7 was stimulated with lipopolysaccharide (LPS, 100 ng/mL), with or without 5AZ (10 
μM). Nitric oxide was quantified by Griess’s method. Expression patterns of inducible nitric oxide synthase (iNOS), interferon regulatory 
factor 1 (IRF-1) and Elk3 were determined by Western blot analysis. For animal study, myocardial infarction (MI) was induced by ligation of 
left coronary artery in mice, and divided into four groups; non MI+saline, non-MI+5AZ, MI+saline, and MI+5AZ. Saline or 5AZ was injected 
(5 mg/kg/d, intraperitoneal injection) every two other day. Cardiac fibrosis was evaluated by Masson’s trichrome stain was performed and 
cardiac function was by echocardiography 2 weeks after MI.
Results:  LPS-induced nitric oxide formation was reduced by 5AZ treatment in RAW264.7 cells (19.37±0.70 pg/mL vs. 10.43±0.90 pg/mL, 
p < 0.05). LPS-induced iNOS mRNA and protein blocked by 5AZ treatment. Next, the kinetics of IRF1, a regulator of iNOS expression, was 
examined. IRF-1 protein was dramatically increased by LPS to peak at 4 hr and then reduced to basal level. In the presence of MG132, a 
proteasome inhibitor, IRF-1 protein sustained maximal level without degradation. On the other hand, IRF-1 protein was significantly highly 
maintained by 5AZ treatment. In animal study, cardiac function was significantly preserved by 5AZ administration. There were significant 
improvements in ejection fraction (53.25±2.55 % vs. 62.50±7.2 %, p < 0.05) and cardiac fibrosis (28.85±5.44% vs. 16.57±6.30%, p < 0.05). 
The number of IRF-1-expressing macrophages in infarcted myocardium was higher in the MI+5AZ group than in the MI+saline group.
conclusion:  5AZ protected post-MI injury by regulation of IRF-1 kinetics to modulate macrophages in infarcted myocardium. This study 
suggested 5AZ as a novel therapeutic intervention for cardiac repair.
